Navigation Links
Fungal protein found to cross blood-brain barrier

(SACRAMENTO, Calif.) In a remarkable series of experiments on a fungus that causes cryptococcal meningitis, a deadly infection of the membranes that cover the spinal cord and brain, investigators at UC Davis have isolated a protein that appears to be responsible for the fungus' ability to cross from the bloodstream into the brain.

The discovery published online June 3 in mBio, the open-access, peer-reviewed journal of the American Society for Microbiology has important implications for developing a more effective treatment for Cryptococcus neoformans, the cause of the condition, and other brain infections, as well as for brain cancers that are difficult to treat with conventional medications.

"This study fills a significant gap in our understanding of how C. neoformans crosses the blood-brain barrier and causes meningitis," said Angie Gelli, associate professor of pharmacology at UC Davis and principal investigator of the study. "It is our hope that our findings will lead to improved treatment for this fungal disease as well as other diseases of the central nervous system."

Normally the brain is protected from bacterial, viral and fungal pathogens in the bloodstream by a tightly packed layer of endothelial cells lining capillaries within the central nervous system the so-called blood-brain barrier. Relatively few organisms and drugs that could fight brain infections or cancers can breach this protective barrier.

The fungus studied in this research causes cryptococcal meningoencephalitis, a usually fatal brain infection that annually affects some 1 million people worldwide, most often those with an impaired immune system. People typically first develop an infection in the lungs after inhalation of the fungal spores of C. neoformans in soil or pigeon droppings. The pathogen then spreads to the brain and other organs.

Unique protein identified

In an effort to discover how C. neoformans breaches the blood-brain barrier, the investigators isolated candidate proteins from the cryptococcal cell surface. One was a previously uncharacterized metalloprotease that they named Mpr1. (A protease is an enzyme a specialized protein that promotes a chemical reaction; a metalloprotease contains a metal ion in this case zinc that is essential for its activity.) The M36 class of metalloproteases to which Mpr1 belongs is unique to fungi and does not occur in mammalian cells.

The investigators next artificially generated a strain of C. neoformans that lacked Mpr1 on the cell surface. Unlike the normal wild-type C. neoformans, the strain without Mpr1 could not cross an artificial model of the human blood-brain barrier.

They next took a strain of common baking yeast Saccharomyces cerevisiae that does not cross the blood-brain barrier and does not normally express Mpr1, and modified it to express Mpr1 on its cell surface. This strain then gained the ability to cross the blood-brain barrier model.

Investigators then infected mice with either the C. neoformans that lacked Mpr1 or the wild-type strain by injecting the organisms into their bloodstream. Comparing the brain pathology of mice 48 hours later, they found numerous cryptococci-filled cysts throughout the brain tissue of mice infected with the wild-type strain; these lesions were undetectable in those infected with the strain lacking Mpr1. In another experiment, after 37 days of being infected by the inhalation route, 85 percent of the mice exposed to the wild-type C. neoformans had died, while all of those given the fungus without Mpr1 were alive.

"Our studies are the first clear demonstration of a specific role for a fungal protease in invading the central nervous system," said Gelli. "The details of exactly how it crosses is an important new area under investigation."

New targeted therapies possible

According to Gelli, their discovery has significant therapeutic potential via two important mechanisms. Either Mpr1 or an aspect of the mechanism by which it crosses the blood-brain barrier could be a target of new drugs for treating meningitis caused by C. neoformans. In a person who develops cryptococcal lung infection, such a treatment would ideally make the fungus less likely to enter the brain and lead to a rapidly fatal meningitis.

Secondly, Mpr1 could be developed as part of a drug-delivery vehicle for brain infections and cancers. An antibiotic or cancer-fighting drug that is unable to cross the blood-brain barrier on its own could be attached to a nanoparticle containing Mpr1, allowing it to hitch a ride and deliver its goods to where it is needed.

"The biggest obstacle to treating many brain cancers and infections is getting good drugs through the blood-brain barrier," said Gelli. "If we could design an effective delivery system into the brain, the impact would be enormous for treating some of these terrible diseases."

Gelli's group is currently pursuing such a nanoparticle drug-delivery system using Mpr1. They are also further investigating the exact molecular mechanism by which Mpr1 breaches the blood-brain barrier.


Contact: Carole Gan
University of California - Davis Health System

Related medicine news :

1. Children failing asthma therapy may have severe asthma with fungal sensitization
2. Texas A&M biologists prove ZOLOFT packs potential to fight fungal meningitis
3. Cases Linked to Fungal Meningitis Now Number 328
4. Fungal Meningitis Outbreak Toll Now 28 Dead, 363 Sickened
5. Flesh-Eating Fungal Infection Can Follow Natural Disasters, Study Finds
6. New Topical Solution for fungal infection by Zeta Clear released to Cure Toenail and Fingernail fungus
7. Valley Fever Fungal Infection on Rise in Southwest
8. Combo Therapy Helps Knock Out Fungal Meningitis
9. Blood Test May Catch Deadly Fungal Infection Quickly
10. Study finds nearly 5 million asthmatics worldwide could benefit from antifungal therapy
11. New €6.1million project to develop new antifungal agents to treat resistant fungal infections
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Live Very Well is excited to announce ... . The multi-carrier insurance exchange platform offers individual vision and dental ... compare, quote and match plans to meet their needs. , Beginning December ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
(Date:11/30/2015)... ... 30, 2015 , ... Stress, anxiety, illness, infection or even a need for ... , Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in ... to tumors. , “Bad headaches that don’t go away, that don’t have ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... ... 30, 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences ... Jurassic to their collection of interactive exhibits within the Kids In Charge! building. In ... guests to get closer than ever to a range of animals as they drink, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015   Royal Philips (NYSE: ... industry,s first MRI guided user interface and automatic scan ... with MR Conditional implants, such as knee and hip ... Radiological Society of North America Annual Meeting (RSNA) . ... diagnostic confidence of this growing patient population. ScanWise Implant ...
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 Cord Blood ... , 9.8 Hospital Management Service Income , ... Medical Insurance Administration Service Income , 2,780 , ... , 89,645 , 94,580 , ... 2,917 , (3.3) Gross Profit 395,857 , ...
Breaking Medicine Technology: